news Invectys raises 1.7 million euros more to finance the clinical development of its therapeutic cancer vaccine 31 March 2015 | By Victoria White Invectys has announced fundraising of 1.7 million euros from its original group of private investors, accelerating the clinical development of INVAC-1...
news Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance 31 March 2015 | By Victoria White Norvatis and Aduro have entered an alliance that is focused on the discovery of cancer immunotherapies and launched a new immuno-oncology research group...
news Pfizer appoints Dr Charles Reay Mackay as Chief Scientific Officer, Inflammation and Immunology Research Unit 31 March 2015 | By Victoria White Pfizer Inc. has announced that Charles Reay Mackay will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit...
news MSD and Intrexon announce agreement for the development and commercialisation of CAR-T cancer therapy 31 March 2015 | By Victoria White Merck Serono and Intrexon Corporation have announced an exclusive collaboration and license agreement to develop and commercialise CAR-T cancer therapies...
news CRT and BioInvent expand collaboration with University of Southampton to develop new immunotherapy treatments for cancer 30 March 2015 | By Victoria White CRT and BioInvent have announced the start of a two-year research collaboration with leading antibody researchers at the University of Southampton...
news Nanoparticles could provide a new treatment option for patients with AMD 30 March 2015 | By Victoria White Around 6.5 million Europeans currently suffer from AMD. Nanoparticles could potentially be used as carriers for drug treatments instead of injections...
news MRC and UCB collaborate to offer access to UCB’s novel antibody discovery platform 30 March 2015 | By Victoria White The MRC and UCB are to launch a collaboration that will provide scientists with access to cutting-edge technologies to discover new monoclonal antibodies...
news Cellectis announces pricing of its initial public offering of American Depositary Shares 30 March 2015 | By Victoria White Cellectis has announced the pricing of its initial public offering of 5,500,000 ADSs at a price to the public of $41.50 per ADS...
news New role uncovered for ‘oldest’ tumour suppressor gene- the retinoblastoma gene 26 March 2015 | By Victoria White Scientists have revealed a brand new function for one of the first cancer genes ever discovered – the retinoblastoma gene...
news Taconic Biosciences and Cellaria Biosciences agree to scientific collaboration to facilitate xenograft use in oncology research 26 March 2015 | By Victoria White Taconic and Cellaria have entered into a scientific collaboration to facilitate use of patient-derived xenografts in animal models for oncology research...
news AstraZeneca to collaborate with the HSCI in search for new diabetes treatments 25 March 2015 | By Victoria White AstraZeneca to collaborate with the HSCI to adapt a technique that creates human beta cells from stem cells to search for new treatments for diabetes...
news Cancer Research UK partners with the Engineering and Physical Sciences Research Council (EPSRC) to inspire innovation 25 March 2015 | By Victoria White Cancer Research UK has partnered with the EPSRC to co-fund multidisciplinary research projects with up to £37.5m in funding available over five years...
news Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research programme focused on autoimmune diseases 24 March 2015 | By Victoria White Bristol-Myers Squibb acquires license from Novo Nordisk for a discovery biologics research programme focused on modulating the innate immune system...
article Meet the editorial board members who influenced the Spring 2015 issue 23 March 2015 | By Caroline Richards (Drug Target Review) Editor Caroline Richards talks about the editorial board members who have influenced the content coming up in the latest issue of Drug Target Review, available in April 2015...
news Confluence Pharmaceuticals signs co-development and marketing agreement with AOP Orphan for Fragile X Syndrome drug 23 March 2015 | By Victoria White Confluence and AOP have signed an agreement to co-develop and market a product for the treatment of Fragile X Syndrome in Europe and the Middle East...
